- Home
- CTMX vs TMQ Comparison
CTMX vs TMQ Comparison
Compare CTMX & TMQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- TMQ
- Stock Information
- Founded
- CTMX 2008
- TMQ 2004
- Country
- CTMX United States
- TMQ Canada
- Employees
- CTMX N/A
- TMQ N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- TMQ Precious Metals
- Sector
- CTMX Health Care
- TMQ Basic Materials
- Exchange
- CTMX Nasdaq
- TMQ Nasdaq
- Market Cap
- CTMX 444.3M
- TMQ 226.7M
- IPO Year
- CTMX 2015
- TMQ N/A
- Fundamental
- Price
- CTMX $2.39
- TMQ $1.84
- Analyst Decision
- CTMX Strong Buy
- TMQ
- Analyst Count
- CTMX 2
- TMQ 0
- Target Price
- CTMX $5.00
- TMQ N/A
- AVG Volume (30 Days)
- CTMX 2.4M
- TMQ 575.1K
- Earning Date
- CTMX 08-07-2025
- TMQ 07-10-2025
- Dividend Yield
- CTMX N/A
- TMQ N/A
- EPS Growth
- CTMX 128.27
- TMQ N/A
- EPS
- CTMX 0.49
- TMQ N/A
- Revenue
- CTMX $147,557,000.00
- TMQ N/A
- Revenue This Year
- CTMX N/A
- TMQ N/A
- Revenue Next Year
- CTMX N/A
- TMQ N/A
- P/E Ratio
- CTMX $4.91
- TMQ N/A
- Revenue Growth
- CTMX 23.81
- TMQ N/A
- 52 Week Low
- CTMX $0.40
- TMQ $0.47
- 52 Week High
- CTMX $3.10
- TMQ $2.09
- Technical
- Relative Strength Index (RSI)
- CTMX 51.66
- TMQ 76.34
- Support Level
- CTMX $2.33
- TMQ $1.30
- Resistance Level
- CTMX $2.79
- TMQ $1.60
- Average True Range (ATR)
- CTMX 0.17
- TMQ 0.12
- MACD
- CTMX -0.01
- TMQ 0.05
- Stochastic Oscillator
- CTMX 42.03
- TMQ 75.02
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.